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Abstract
The avian coronavirus infectious bronchitis virus (IBV) is the causative agent of the respiratory disease infectious bronchitis
of domestic fowl, and is controlled by routine vaccination. To explore the potential use of IBV as a vaccine vector a reverse
genetics system was utilised to generate infectious recombinant IBVs (rIBVs) expressing the reporter genes enhanced green
fluorescent protein (eGFP) or humanised Renilla luciferase (hRluc). Infectious rIBVs were obtained following the replacement
of Gene 5 or the intergenic region (IR) with eGFP or hRluc, or the replacement of ORFs 3a and 3b with hRluc. The
replacement of Gene 5 with an IBV codon-optimised version of the hRluc gene also resulted in successful rescue of
infectious rIBV. Reporter gene expression was confirmed by fluorescence microscopy, or luciferase activity assays, for all
successfully rescued rIBVs following infection of primary chick kidney (CK) cells. The genetic stability of rIBVs was analysed
by serial passage on CK cells. Recombinant IBV stability varied depending on the genome region being replaced, with the
reporter genes maintained up to at least passage 8 (P8) following replacement of Gene 5, P7 for replacement of the IR and
P5 for replacement of ORFs 3a and 3b. Codon-optimisation of the hRluc gene, when replacing Gene 5, resulted in an
increase in genome stability, with hRluc expression stable up to P10 compared to P8 for standard hRluc. Repeated
passaging of rIBVs expressing hRluc at an MOI of 0.01 demonstrated an increase in stability, with hRluc expression stable up
to at least P12 following the replacement of Gene 5. This study has demonstrated that heterologous genes can be
incorporated into, and expressed from a range of IBV genome locations and that replacement of accessory Gene 5 offers a
promising target for realising the potential of IBV as a vaccine vector for other avian pathogens.
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Introduction
Coronaviruses are positive-sense RNA viruses with large
genomes ranging in size from approximately 26 to 31 kb, and
are known to infect a wide range of mammalian and avian species,
with species and tissue specific tropisms. All coronaviruses share a
similar genome organisation with Gene 1, the replicase gene,
located at the 59 end of the genome and the structural and group-
specific accessory genes clustered at the 39 end. A process of
discontinuous transcription during negative strand synthesis,
regulated by short AU rich sequences known as transcription
regulatory sequences (TRSs), leads to expression of the structural
and accessory proteins as a nested set of subgenomic (sg) mRNAs
(reviewed in [1–3]). The avian gammacoronavirus IBV is a highly
infectious pathogen of domestic fowl that causes disease in
chickens of all ages and despite vaccination, using both live
attenuated and inactivated vaccines, is responsible for major
economic losses to poultry industries worldwide as a result of poor
weight gain and decreased egg production [4–9].
The large size of coronavirus genomes, combined with the
possibility of expressing heterologous genes via the generation of
novel sg mRNAs, has meant that coronaviruses have long been
attractive targets for use as viral-vector vaccines and gene delivery
systems. Previous work by ourselves and others has shown that
heterologous genes can be expressed utilising TRSs from
coronavirus defective RNAs (D-RNAs) in the presence of helper
virus [10–14]. In recent years a number of reverse genetics systems
have been successfully developed to produce full-length cDNAs
from several coronaviruses including TGEV, human coronavirus
229E, SARS-CoV and human coronavirus NL63 [15–19]; with
these advances making it possible to investigate the potential of
using coronaviruses as vaccine vectors. A reverse genetics system
for IBV, utilizing vaccinia virus, has also been established and so
made it possible to explore the use of rIBVs for vaccine
development [20–22].
To date a number of studies have demonstrated the generation
of infectious recombinant coronaviruses that are able to express
heterologous genes, a key requirement of any vaccine vector [23–
27]. These studies, as outlined by de Haan et al. [28,29], showed
that the expression of heterologous proteins may be dependent on
a number of factors, including the genetic background of the virus,
the spatial location in the virus genome at which the heterologous
gene is inserted and, if replacing genes, how essential these genes
are to the replication of the coronavirus. Due to the nature of
coronavirus sg mRNA transcription the expression of heterologous
genes may be achieved by expression from an existing sg mRNA
either via insertion of a gene cassette or by replacement of existing
genes. Alternatively, heterologous genes can be expressed from an
additional, newly synthesised sg mRNA as demonstrated from IBV
D-RNAs [12,14] or TGEV minigenomes [30], although these
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were often found to be genetically unstable. Recombinant viruses
consisting of full-length virus genomes showed that stability was
often greatest following the replacement of the non-essential
accessory genes [24,27,29,31], while alterations to coronavirus
structural genes appeared to be less well tolerated with reduced
virus stability, or an inability to rescue infectious virus [24,32].
Given the potential for coronaviruses as vaccine vectors, and the
continual requirement for IBV vaccination, IBV has the potential
to be a suitable vaccine vector for the generation of bivalent
vaccines that protect against not only IBV, but also additional
avian diseases as determined by the expression of a heterologous
gene. Other avian viruses such as the paramyxovirus Newcastle
disease virus, and the avipoxvirus fowlpox virus have previously
been evaluated for use as vectors, not only as vaccines for
veterinary use [33,34] but also for vaccine and gene therapy use in
humans [35–37] and reviewed in [38,39] demonstrating the
potential for using avian viruses as vectors. Additionally, IBV
possesses two accessory genes, Gene 3 and Gene 5, and the
recently characterised IR, all of which have been shown to be
dispensable for virus replication in cell culture [27,40–42] and
therefore provide potential targets for replacement with a
heterologous gene.
In this study we used our IBV reverse genetics system [20,21],
based on the avirulent Beaudette strain of IBV, to generate rIBVs
in which different regions of the IBV genome were replaced with
the reporter genes eGFP or hRluc. The resulting rIBVs were
assessed to investigate whether: (1) the size and type, (2) the spatial
position or (3) the nucleotide sequence of the gene introduced were
important factors in determining the possibility for utilising IBV as
a vaccine vector. Reporter genes were inserted under the control
of existing TRSs in the case of the replacement of Gene 3 and
Gene 5, or under the control of an additionally inserted copy of an
IBV canonical consensus TRS in the case of the replacement of
the IR. Successfully rescued viruses were characterised and
subsequently investigated for genetic stability. The effect of
codon-optimisation of the heterologous gene to be more ‘IBV-
like’ in nucleotide sequence was also investigated. Our results
demonstrated that heterologous gene expression could be achieved
in cell culture for all successfully rescued rIBVs, although genome
stability varied depending on the genomic location of the reporter
gene and the MOI at which rIBVs were passaged in vitro. The
results of this study suggest that the replacement of Gene 5 with
heterologous genes represents a promising target for the genera-
tion of IBV-based vaccine vectors.
Materials and Methods
Ethics Statement
Primary CK cells were prepared by The Pirbright Institute cell
culture department from chickens produced in the Institute’s
poultry production unit. The chickens were sacrificed by trained
staff under a schedule 1 procedure, cervical neck dislocation, a
procedure that does not fall under any UK Home Office licence
requirements as no procedures were carried out on live animals
and therefore did not fall under any local or EU ethical
requirements. The kidneys were removed from the sacrificed
chickens for preparation of the primary CK cell cultures. The
work was done in a designated establishment, The Pirbright
Institute, Compton Laboratory.
Cells and Viruses
Primary chicken kidney (CK) cells were prepared from 2-3 week
old specific pathogen free (SPF) Rhode Island Red chickens as
described previously [43]. All IBVs were propagated and titrated
on primary CK cells using BES (N, N-Bis(2-hydroxyethyl)-2-
aminoethanesulphonic acid) cell maintenance medium [44].
Construction of Modified IBV cDNA Plasmids and
Generation of Recombinant Viruses
All recombinant viruses were generated with a genomic
backbone of Beau-R and all nucleotide numbers refer to genome
positions in this virus (GenBank Number AJ311317). Reporter
genes eGFP and hRluc were amplified from plasmids pEGFP-C1
(Clontech) and pGL4.75hRluc/CMV (Promega), respectively.
Modified fragments of IBV cDNA for the replacement of Gene
5 by eGFP or hRluc, between nucleotides 25479 and 25702
inclusively, were generated by overlapping PCR. Three fragments
were amplified with primer pairs: (1) 24979M – 25487IR (24979M: 59-
TTTGGCGCGCCGCTAAGTGTGAACCAGACCACTTGCC-
39 and 25487IR-eGFP: 59-GCTCCTCGCCCTTGCTCACCAT-
CGTCCGTATTTGTTAAGTTTTTG-39 or 25487IR-hRluc: 59-
GTCGTACACCTTGGAAGCCATCGTCCGTATTTGTTAA-
GTTTTG-39), (2) eGFP or hRluc (eGFP-F: 59-CAAAAACT-
TAACAAATACGGACGATGGTGAGCAAGGGCGAGGAGC-
39 and eGFP-R: 59-GCTATTGCTCCGCGAAAAGGTTAT-
TACTTGTACAGCTCGTCC-39) or (hRluc-F: CAAAAACT-
TAACAAATACGGACGATGGCTTCCAAGGTGTACGAC-39
and hRluc-R: 59- GCTATTGCTCCGCGAAAAGGTTATTAC-
TGCTCGTTCTTCAGC-39) and (3) 257025b – 26250N (257025b-
eGFP: 59- GGACGAGCTGTACAAGTAATAACCTTTTCGC-
GGAGCAATAGC-39 or 257025b-hRluc: 59- GCTGAAGAAC-
GAGCAGTAATAACCTTTTCGCGGAGCAATAGC-39 and
26250N: 59- CCCTTAATTAAGTCGATCTAGATTTAGTAT-
CAGCACCC-39). Underlined nucleotides are derived from
reporter gene sequences and bold italics show inserted restriction
sites AscI and PacI. Fragments were joined by PCR, and cloned into
AscI/PacI digested pGPTNEB193 as described previously
[20,42,44–46] to generate plasmids pGPT-eGFPD5ab and pGPT-
hRlucD5ab.
To create altered nucleotide gene sequences for IBV codon-
optimised eGFP (IBVeGFP) and hRluc (IBVhRluc) a codon usage
table was generated from IBV coding sequences (Table 1). Wild
type amino acid sequences for eGFP (pEGFP-C1) and hRluc
(pGL4.75hRluc/CMV) were back translated utilizing the alterna-
tive IBV preferred codons, as per Table 1, to generate IBV codon-
optimised reporter gene sequences which were subsequently
synthesised within the context of the IBV cDNA fragment
described above by GeneartH (Life Technologies). Only the
synthetic sequence representing IBVhRluc could be cloned into
pGPTNEB193 by GeneartH to give plasmid pGPT-IBVhRluc-
D5ab.
For the replacement of the IR by eGFP or hRluc between
nucleotides 25192 and 25459 reporter gene sequences were
amplified by PCR to add 59-NheI and 39-XmaI restriction sites
along with a copy of the Gene 5 TRS at the 59 end: (eGFP-F: 59-
TTTGCTAGCGGCCAACTTAACAAATACGGACGATGGT-
GAGCAAGGGCGAGG and eGFP-R: 59- AAACCCGGGT-
TATTACTTGTACAGCTCGTCCATGCC-39) or (hRluc-F: 59-
TTTGCTAGCGGCCAACTTAACAAATACGGACGATGGCTTC-
CAAGGTGTACG-39 and hRluc-R: 59- AAACCCGGGTTAT-
TACTGCTCGTTCTTCAGCACGCGC-39). Underlined nucle-
otides are derived from reporter gene sequences and bold italics
show inserted restriction sites NheI and XmaI. Sequences were
cloned into NheI/XmaI digested pGPTDIR as described previously
[42] to give plasmids pGPT-eGFPDIR and pGPT-hRlucDIR.
For the replacement of ORFs 3a and 3b between nucleotides
23857 and 24203 inclusively modified IBV cDNA fragments were
synthesised and cloned into pGPTNEB193 by GeneartH to give
IBV as a Vector for Heterologous Genes
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plasmids pGPT-eGFPD3ab and pGPT-hRlucD3ab. A single copy
of the duplicated Gene 5 TRS and flanking nucleotides (59-
GUUUUACUUAACAAAUACGGACG-39) was inserted be-
tween the reporter gene termination codon and the ORF 3c
initiation codon beginning at nucleotide 24204 for transcription of
ORF 3c sg mRNA.
The control rIBV BeauRD5ab was generated by deletion of the
IBV cDNA sequence, nucleotides 25451–25693, covering the gene
5 TRS, ORF 5a and the N-terminal end of ORF 5b from pGPT-
K5ScAUG5b [40]. Essentially the introduced KpnI site was treated
with T4 DNA polymerase and ligated to the introduced ScaI site
downstream of the ORF5b AUG resulting in plasmid pGPT-
D5ab.
Modified regions of the IBV cDNA within plasmids pGPT-
D5ab, pGPT-eGFPD5ab, pGPT-hRlucD5ab, pGPT-IBVhRluc-
D5ab, pGPT-eGFPDIR, pGPT-hRlucDIR, pGPT-eGFPD3ab
and pGPT-hRlucD3ab were introduced into the IBV Beaudette
full-length cDNA within the vaccinia virus genome by homologous
recombination using transient dominant selection as described
previously [20,44,47]. Infectious rIBVs were recovered from DNA
isolated from the recombinant vaccinia viruses containing the
correctly modified IBV cDNAs and passaged four times on CK
cells prior to experimental use [20,44,47].
RNA extraction and RT-PCR
Viral RNA was extracted from cell supernatants using the
RNeasy Mini Kit (Qiagen) following the manufacturer’s instruc-
tion for the RNA clean up protocol. cDNA was synthesised using
SuperScript III (Life Technologies) and a random primer as per
manufacturer’s instructions. cDNA was amplified by PCR using
primer pairs that flanked the inserted reporter gene: for D5ab
recombinant viruses (59-GAGCTATTAACGGTGTTACC-39)
and (59-AATCTAATCCTTCTCTCAGA-39), for DIR recombi-
nant viruses (59-GAATGGTGTTCTTTATTG-39) and (59-
TCTAACACTCTAAGTTGAG-39), and for D3ab recombinants
(59-TGACGAATTGTCAAAATG-39) and (59-AGACAGA-
CACGCAAACACTG-39). PCR cycling parameters were as
follows: 1 cycle of 94uC for 2 min; 25 cycles of 94uC for 30 sec,
50uC for 30 sec, 72uC for 30 sec; and a final extension step of
72uC for 2 min.
Growth Kinetics of rIBVs
Individual wells of six-well plates of confluent CK cells were
infected with 16105 pfu of virus and incubated for 1 h at 37uC,
5% CO2 after which cells were washed twice with PBS and 2 ml of
fresh 16BES media added. Extracellular virus was harvested at 1,
8, 12, 24, 48 and 72 hours post infection (hpi) and subsequently
analysed in triplicate by plaque assay on CK cells for progeny
virus.
Luciferase Assays
Cell lysates were prepared from CK cells infected with
recombinant IBVs expressing hRluc gene and luciferase activity
measured using the Renilla Luciferase Assay System (Promega) as
per manufacturer’s instructions. Relative light unit (RLU) values
were obtained using a GloMaxH 20/20 luminometer (Promega)
with integration over 10-seconds with a 2-second delay.
Northern Blot Analysis
Total RNA was extracted from CK cells 24 hpi using the
RNeasy Mini Kit (Qiagen) and mRNA purified using the
Poly(A)PuristTM MAG Kit (Ambion) according to manufacturer’s
instructions. Northern blot analysis was carried out with the
NorthernMaxH-Gly Kit (Ambion) as described previously [42].
Briefly, viral mRNA transcripts were denatured at 50uC for
30 min in glyoxal load dye followed by separation on a 0.8% LE-
agarose gel. RNA was transferred to BrightStarH-Plus positively
charged nylon membrane (Ambion) using capillary action for 2 h,
cross-linked by treatment with UV light using the auto-crosslink
function on a Stratalinker UV Crosslinker (Stratagene) and
prehybridised for 30 min with ULTRAhybH buffer at 42uC. Blots
were probed with a DNA probe specific to the 39 end of IBV and
hybridised overnight at 42uC followed by washing and develop-
ment with the BrightStarH BioDetectTM Kit.
Western Blot Analysis
Confluent monolayers of CK cells were infected with 16105 pfu
virus. At 20 hpi cells were washed twice with PBS, lysed in buffer
containing 20 mM Tris, 150 mM NaCl, 5 mM EDTA, 0.3%
Triton X100 and 1X protease inhibitor cocktail (Sigma) and
clarified by centrifugation. Samples were denatured in NuPAGEH
LDS Sample Buffer (4X) (Life Technologies), heated for 10 min at
70uC, separated by polyacrylamide gel electrophoreses (PAGE)
using NuPAGEH 10% Bis-Tris pre-cast polyacrylamide gels (Life
Technologies) and transferred to nitrocellulose membrane (Amer-
sham). Separated proteins were probed with polyclonal rabbit sera
against IBV diluted 1:2500 and a polyclonal antibody against beta-
actin diluted 1:500 (Abcam). Enhanced GFP expression was
confirmed using a polyclonal antibody against GFP diluted 1:1000
(Abcam) and Renilla luciferase expression was confirmed using a
polyclonal antibody against Renilla luciferase diluted 1:1000 (MBL
International). Bound antibody was visualized using an enhanced-
chemiluminescence detection system (ECL) (Millipore).
Results
Design of recombinant IBVs
In order to investigate the potential of IBV as a vaccine vector
we first designed a series of rIBVs that could be used to assess the
ability of IBV to express heterologous proteins and subsequently
determine the stability of each rIBV. Based on the Beau-R
Table 1. IBV Codon Usage.
Codon Frequency per thousand (Number)*
UUU 42.3 (12136) UCU 22.2 (6359 UAU 29.9 (8580) UGU 22.3 (6395)
UUC 10.0 (2859) UCC 3.1 (879) UAC 12.2 (3487) UGC 5.8 (1653)
UUA 18.6 (5339) UCA 18.3 (5254) UAA 1.3 (376) UGA 1.0 (292)
UUG 14.3 (4101) UCG 3.0 (871) UAG 0.4 (113) UGG 14.8 (4247)
CUU 24.9 (7142) CCU 18.5(5312) CAU 8.7 (2500) CGU 12.2 (3501)
CUC 5.4 (1541) CCC 5.0(1428) CAC 5.3 (1533) CGC 5.6 (1612)
CUA 11.4 (3266) CCA 20.0 (5733) CAA 24.2 (6937) CGA 2.5 (708)
CUG 7.2 (2057) CCG 4.0 (1138) CAG 18.8 (5381) CGG 1.5 (424)
AUU 27.2 (7813) ACU 26.5 (7618) AAU 44.0 (12624) AGU 21.6 (6186)
AUC 5.6 (1596) ACC 4.8 (1379) AAC 12.8 (3671) AGC 5.9 (1690)
AUA 19.7 (5643) ACA 20.9 (6004) AAA 31.1 (8924) AGA 16.0 (4605)
AUG 15.5 (4434) ACG 4.9 (1415) AAG 30.6 (8769) AGG 8.2 (2341)
GUU 33.3 (9556) GCU 25.7 (7371) GAU 38.3 (10980) GGU 39.4 (11297)
GUC 7.7 (2198) GCC 8.0 (2302) GAC 15.6 (4482) GGC 8.1 (2332)
GUA 18.8 (5383) GCA 27.4 (7874) GAA 26.2 (7506) GGA 18.6 (5347)
GUG 14.6 (4199) GCG 6.7 (1916) GAG 17.4 (4979) GGG 4.7 (1353)
*IBV codon usage was derived from 785 coding sequences (286941 codons).
doi:10.1371/journal.pone.0067875.t001
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molecular clone of the Beaudette-CK strain of IBV [21], we
designed eight rIBVs in which three different IBV genome regions,
Gene 5, ORFs 3a and 3b or the IR, were replaced with the
reporter genes eGFP or hRluc, or codon-optimised reporter genes
IBVeGFP and IBVhRluc (Figure 1). The growth characteristics of
the rIBVs were compared to the control viruses BeauRD5ab (this
paper), BeauRD3ab [41] and BeauRDIR [42] in which the regions
being replaced were deleted. In the design of each construct
measures were taken to ensure that the transcription of other IBV
genes was not affected by the loss of virus sequences or the
incorporation of the reporter gene sequences. Recombinant IBVs,
BeauR-eGFPD5ab and BeauR-hRlucD5ab, consisted of direct
replacement of IBV Gene 5 sequence, beginning at the ORF 5a
initiation codon, and ending at amino acid seven of ORF 5b in
order to maintain the genomic sequence upstream of the N gene
TRS. Expression of eGFP or hRluc from BeauR-eGFPD5ab and
BeauR-hRlucD5ab was achieved via the existing Beaudette Gene
5 TRS.
Recombinant IBVs, BeauR-eGFPD3ab and BeauR-hRluc-
D3ab, consisted of the direct replacement of ORF 3ab sequence,
beginning at the second nucleotide (U) of the ORF 3a initiation
codon in order to preserve the overlapping spike termination
codon. A stretch of 20 nucleotides, corresponding to the 39 end of
ORF 3b, was maintained to avoid disruption of ORF 3c, encoding
the envelope (E) protein. The introduced reporter genes, replacing
ORFs 3ab, were expressed utilising the existing Gene 3 TRS. To
ensure expression of the E protein the insertion of an artificial
TRS was required directly downstream of the reporter gene
sequence for the transcription of a sg mRNA for translation of the
E protein. As the full extent of the sequences required for efficient
sg mRNA transcription are currently unknown for IBV we
designed a TRS containing a copy of the consensus IBV TRS with
flanking nucleotides derived from the Gene 5 TRS (59-
GUUUUACUUAACAAAUACGGACG-39) based on our knowl-
edge of the expression of foreign genes from IBV D-RNAs [12,14].
Inclusion of six 59-flanking, and nine 39-flanking nucleotides was
based on an extension of previous findings demonstrating that the
four nucleotides flanking either side of the consensus sequence
were important for efficient sg mRNA expression, and that these
nucleotides would increase complementarity with the leader
sequence as presumably is the case for Gene 5 expression [48].
Recombinant IBVs, BeauR-eGFPDIR and BeauR-hRlucDIR,
were designed to express reporter genes from a novel sg mRNA.
The Beaudette IR sequence was replaced, between nucleotides
25192 and 25459 of the Beau-R genome, with a reporter gene
construct in which a copy of the consensus IBV TRS with 39
flanking nucleotides derived from the Gene 5 TRS (59-CUUAA-
CAAAUACGGACG-39), was placed upstream of the reporter
gene sequence for the transcription of an additional sg mRNA for
translation of eGFP or hRluc. As with the inserted TRS for
expression of E from BeauR-hRlucD3ab 39-flanking nucleotides
were added to increase complementarity to the leader sequence
and improve chances of sg mRNA synthesis. In this case no 59-
flanking nucleotides were added, as due to the cloning procedure
required for these rIBVs additional sequences would be generated
59 to the TRS that it was hoped would act to position to TRS
correctly for sg mRNA synthesis and provide additional, although
limited, sequence complementarity.
In addition to genome position, we also investigated the effect of
codon-optimisation of the heterologous gene by redesigning the
gene sequence so that codon usage maximally represented that of
IBV. Using a codon usage table (details at www.kazusa.or.jp/
codon/) (Table 1) and the Emboss backtransseq programme
(details at http://emboss.open-bio.org/) new eGFP and hRluc
nucleotide sequences, IBVeGFP and IBVhRluc, were generated
and synthesised with 34 and 29% of nucleotides changed,
respectively (Figure 2). The final two rIBVs, BeauR-IBVeGFP-
D5ab and BeauR-IBVhRlucD5ab, were subsequently designed in
which Gene 5 was replaced, as above, with the synthesised codon-
optimised reporter genes.
Characterisation of rIBVs expressing eGFP or hRluc
following replacement of Gene 5
Utilising our IBV reverse genetics system [20,21] we rescued
two replicates, R1 and R2, of rIBVs BeauR-eGFPD5ab, BeauR-
hRlucD5ab and BeauR-IBVhRlucD5ab, in which Gene 5 was
replaced with reporter genes eGFP, hRluc or IBVhRluc,
respectively. A potential rIBV, BeauR-IBVeGFPD5ab containing
the codon-optimised eGFP gene, was not possible, as we were
unable to insert a copy of the IBV codon-optimised eGFP
sequence into the selection plasmid required for modifying the
IBV cDNA in our reverse genetics system. Each rescued rIBV was
subsequently passaged to P4 on CK cells for further analysis. The
successful rescue of infectious rIBVs was confirmed by formation
of IBV-induced plaques on CK cells (Figure 3A), although it was
observed that plaques for all D5ab rIBVs were approximately
2 mm smaller in diameter than plaques observed for wild type
Beau-R.
To analyse the effects of deleting IBV Gene 5, and subsequent
insertion of the reporter genes in place of Gene 5, the replication
kinetics of R1 isolates of BeauR-eGFPD5ab, BeauR-hRlucD5ab
and BeauR-IBVhRlucD5ab were compared to wild type Beau-R
and control BeauRD5ab viruses (Figure 3B). Similar replication
kinetics were observed for all three rIBVs and for control virus
BeauRD5ab. However, peak titres at 24 hpi for all the rIBVs
lacking the Gene 5 proteins were approximately 1-log10 lower, at
16106 pfu/ml, than wild type Beau-R. Additionally, a 2-log10
increase in titre was noted for Beau-R compared to a,0.5-log10
increase at 8 hpi for all rIBVs suggesting a delay in replication or
release of the rIBVs lacking Gene 5. Combined with the
observation of smaller plaque sizes these results suggested that
the replacement or deletion of Gene 5 had a minor detrimental
effect on virus replication in CK cells. Northern blot analysis of
rIBVs sg mRNAs demonstrated an increase in the size of the sg
mRNA initiated from the Gene 5 TRS when compared to
parental virus Beau-R, and which corresponded to the presence of
eGFP or hRluc sequences (Figure 3C). Corresponding expected
increases in size, due to the presence of the reporter gene
sequences, were also observed for all the larger sg mRNAs
synthesised upstream of the Gene 5 replacement site, due to the
nested nature of coronavirus sg mRNAs.
Heterologous protein expression was confirmed for the three
rIBVs by western blot analysis of rIBV-infected CK cell lysates
using anti-GFP and anti-Renilla luciferase antibodies (Figure 3D).
In addition, GFP-induced fluorescence was observed in CK cells
infected with P4 of rIBV BeauR-eGFPD5ab (Figure 4A). To
confirm the expression of active Renilla luciferase from rIBVs
BeauR-hRlucD5ab and BeauR-IBVhRlucD5ab, luciferase activity
was measured in CK lysates during time course assays for
replication kinetics, and was found to correlate with levels of virus
titre during infection (Figure 4B). When compared to BeauR-
hRlucD5ab, and subsequently R2 of BeauR-IBVhRlucD5ab, the
luciferase activity of BeauR-IBVhRlucD5ab R1 reached approx-
imately 2-log10 lower peak levels at 24 hpi. Sequence analysis of
P4 of BeauR-IBVhRlucD5ab R1 established that a mutation had
arisen in the codon-optimised hRluc gene during initial passage of
rescued virus on CK cells. The mutation, an insertion of two uracil
residues at nucleotide position 787 within the codon-optimised
IBV as a Vector for Heterologous Genes
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hRluc gene, led to a frameshift and alteration of the hRluc amino
acid sequence downstream of amino acid 262. This frameshift
resulted in a modified IBVhRluc protein, eight amino acids longer
than the wild type codon-optimised version (Figure 5). Analysis of
BeauR-IBVhRlucD5ab R2 demonstrated luciferase activity levels
more closely mirroring those of BeauR-hRlucD5ab, suggesting the
mutation within the hRluc gene of BeauR-IBVhRlucD5ab R1 was
the cause of the observed reduction in luciferase activity
(Figure 4B).
Characterisation of rIBVs expressing eGFP or hRluc
following replacement of the Beaudette IR
As with the replacement of Gene 5 we used our IBV reverse
genetics system to generate two replicates each of rIBVs BeauR-
eGFPDIR and BeauR-hRlucDIR, in which the heterologous gene
sequences replaced the Beaudette IR sequence between the end of
the M gene and upstream of the Gene 5 TRS. We have recently
shown that the IBV IR is produced as a novel sg mRNA and
encodes a fifth IBV accessory protein, however, in Beaudette the
IR contains deletions rendering the sequence more likely a non-
coding region [42]. The successful rescue of infectious rIBVs was
confirmed by formation of IBV-induced plaques on CK cells
(Figure 6A), which were compared to the plaques generated by
wild type Beau-R and control virus BeauRDIR. In contrast to the
D5ab rIBVs, deletion of the Beaudette IR did not result in smaller
plaque sizes when compared to Beau-R (Figure 6A). However,
plaque size differences were observed depending on whether the
IR sequence was replaced by eGFP or hRluc. Plaques produced
Figure 1. Design of rIBV constructs. Schematic of wild type Beau-R and rIBV genomes displaying position of reporter genes; with eGFP shown as
green boxes and hRluc shown as yellow boxes. As the schematic diagrams of the rIBVs containing codon optimised versions, IBVeGFP and IBVhRluc,
of the eGFP and hRluc genes in place of Gene 5 were the same as the normal reporter genes separate diagrams are not included. Expanded regions
show the nature of the TRS controlling expression of each reporter gene with use of existing sequences referred to as Gene 5 TRS or Gene 3 TRS. For
D5ab rIBVs the nucleotides remaining for 5b are given. For DIR rIBVs underlined sequence relates to residual IR sequence and cloning sites required
for construction of reverse genetics selection vector. In bold is shown the Gene 5 8-nucleotide TRS plus nine 39-flanking nucleotides. In addition for
D3ab rIBVs the six 59-flanking nucleotides from the Gene 5 TRS are shown in italics.
doi:10.1371/journal.pone.0067875.g001
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from BeauR-eGFPDIR were approximately 1.5 mm smaller in
diameter than those observed from BeauR-hRlucDIR (Figure 6A).
Investigation of the replication kinetics of the rIBVs revealed lower
peak titres at 24 hpi for BeauR-eGFPDIR of 56105 pfu/ml when
compared to peak titres, of approximately 16107 pfu/ml, for
BeauR-hRlucDIR (Figure 6B); a result consistent with the plaque
sizes observed for these viruses. Both Beau-R and BeauRDIR had
similar replication kinetics, showing maximal peak titres of
56107 pfu/ml at 24 hpi and supporting the plaque assay data;
indicating that removal of the IR sequence per se did not have any
effect on the growth and replication of rIBV BeauRDIR.
Pursuing the result of the initial observed differences between
the replication kinetics of the rIBVs BeauR-eGFPDIR and BeauR-
hRlucDIR, the replication kinetics of rIBV BeauR-eGFPDIR R2
were also investigated and found to be identical to those of rIBV
BeauR-eGFPDIR R1 (Figure 6C). This indicated that the
replication differences observed between BeauR-eGFPDIR and
BeauR-hRlucDIR resulted from the insertion of different reporter
genes, and suggested that, in terms of virus replication, eGFP was
not as well tolerated as hRluc at this genome position. While no
differences in replication kinetics were observed for BeauR-
eGFPDIR R1 and R2, sequence analysis of P4 stocks of all DIR
rIBVs revealed that BeauR-eGFPDIR R1 did contain an
additional change; a double mutation of 25770URA and
25771URA leading to the introduction of a premature termination
codon within ORF 5b, resulting in the truncation of the 5b protein
from 82 to 29 amino acids. A similar mutation has been previously
identified in rIBVs with a Beau-R background [45] however,
indicating that this particular mutation is not associated with the
presence of heterologous genes.
Construction of rIBVs BeauR-eGFPDIR and BeauR-hRlucDIR
required the insertion of a copy of the consensus Beaudette TRS,
CUUAACAA, upstream of the reporter gene sequence for the
transcription of an additional sg mRNA from which eGFP or
hRluc proteins could be translated. However, northern blot
analysis (Figure 6D) revealed that no novel sg mRNAs were
generated from the introduced TRS positioned between the M
gene and Gene 5. Instead, the non-canonically transcribed sg
mRNA recently confirmed for the IR [42] was increased in size as
would be predicted for the presence of the reporter gene
sequences. Investigation of the larger IR sg mRNA sequences
confirmed that they were transcribed via the naturally occurring
non-canonical TRS for the IR sg mRNA, identified at nucleotide
position 25075 within the M gene of the Beaudette sequence by
Bentley et al. [42], and not via the artificial copy of the IBV
consensus TRS (Figure 7).
Western blot analysis of proteins in rIBV-infected CK cell
lysates demonstrated the presence of either eGFP or hRluc
(Figure 6E), thus confirming that translation of eGFP or hRluc was
not affected by the unexpected observation that the proteins were
produced from an existing sg mRNA, rather than from a new sg
mRNA generated from an additionally inserted TRS. However,
because of the naturally low levels of the IR sg mRNA due to
transcription from a non-canonical TRS [42], we consequently
observed lower levels of fluorescence from BeauR-eGFPDIR than
from BeauR-eGFPD5ab (Figure 4A). Reduced protein expression
levels were confirmed by the observation that Renilla luciferase
activity from BeauR-hRlucDIR was also lower in comparison to
that observed from BeauR-hRlucD5ab, with peak activity at
24 hpi approximately 2-log10 lower (Figure 4B). It is possible that
these reduced protein expression levels may also be a result of
reduced translation due to the presence of the wild type IR AUG
upstream of the reporter gene AUG; a consequence of the cloning
stages of the reverse genetics. This would need to be investigated
further to determine the exact cause of the protein levels observed.
Characterisation of rIBVs expressing hRluc following
replacement of ORFs 3a and 3b of Gene 3
Using reverse genetics we were able to rescue two replicates of
rIBV BeauR-hRlucD3ab, in which ORFs 3a and 3b were replaced
by hRluc. For generation of rIBV BeauR-eGFPD3ab we found
that although the initial stages of the reverse genetics were
successful, infectious rIBV could not be rescued by passage on CK
cells, or in embryonated hens’ eggs. The successful rescue of two
replicates of rIBV BeauR-hRlucD3ab was demonstrated by the
formation of IBV-induced plaques in CK cell culture (Figure 8A).
While similar sized plaques had been observed between replicates
of the D5ab and DIR recombinants this was not the case for
BeauR-hRlucD3ab, where a mixture of plaque sizes was visible for
R2. Such a variation in plaque size is often an indication of a
mixed population and the observed plaque phenotype suggested
that BeauR-hRlucD3ab R2 was not rescued as a stable molecular
clone. This was confirmed by sequence analysis which identified
sequence variation in a region initiating approximately 40 nts
from the 39 end of the hRluc gene in R2 and extending into the
inserted TRS required for the transcription of a sg mRNA for the
E protein (data not shown). Additionally, a 3 nt deletion was also
observed within the inserted canonical, CUUAACAA, TRS for
the E protein in R1 of BeauR-hRlucD3ab, resulting in a non-
canonical TRS sequence of CUUAA. The presence of nucleotide
changes and deletions in this region suggested that the stability of
these viruses was not optimal and that the introduced sequences
required to ensure transcription of the genes were not well
tolerated. These observations may offer an explanation for the
failure of rIBV BeauR-eGFPD3ab to rescue as fatal deletions may
have arisen in this region during the initial stages of rescue and/or
passage.
The replication kinetics of rIBV BeauR-hRlucD3ab R1 were
investigated and demonstrated peak titres at 24 hpi that were
similar to control virus BeauRD3ab with both approximately 1-
log10 lower than wild type Beau-R virus (Figure 8B). It should be
noted that transcription of the sg mRNA for expression of the E
gene from BeauRD3ab was from the normal Gene 3 TRS [41].
Heterologous gene expression was confirmed by northern blot
analysis (Figure 8C) with an expected increase in size of the Gene 3
sg mRNA observed when compared to parental virus Beau-R.
However, the size of the hRluc sg mRNA of R2 appeared smaller
than that of R1 suggesting that the issues identified above, and
confirmed by sequence analysis, may be due to deletions within
the hRluc gene. Analysis of IBV RNA from CK cells infected with
BeauR-hRlucD3ab R1 identified a low abundant sg mRNA, at the
expected position above the M gene sg mRNA, representing the sg
mRNA produced from the inserted TRS for the expression of the
E protein. The low abundance of this new sg mRNA could result
from an effect of the observed deletion in the introduced TRS,
and/or may result from the fact that synthesis of a sg mRNA
Figure 2. Codon-optimised reporter gene sequences. Wild type reporter gene sequences were back translated using the IBV preferred codon,
as indicated in Table 1, to generate a new nucleotide sequence codon-optimised for IBV. Wild type nucleotide sequences for (A) eGFP and (B) hRluc
were aligned to codon-optimised sequences IBVeGFP and IBVhRluc, respectively. Nucleotides highlighted in black remained the same and those that
modified to give IBV-optimised codons highlighted in grey, the amino acid sequences are shown below the alignments.
doi:10.1371/journal.pone.0067875.g002
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Figure 3. Characterisation of rIBVs with replacement of Gene 5 with eGFP or hRluc. (A) Monolayers of CK cells were infected with wild type
virus (Beau-R), control virus (BeauRD5ab) or P4 of rIBVs BeauR-eGFPD5ab, BeauR-hRlucD5ab or BeauR-IBVhRlucD5ab and cytopathic effect analysed
by plaque assay. (B) Growth kinetics of Beau-R, BeauRD5ab and rIBVs in CK cells. Extracellular virus was harvested at various times post infection and
the progeny virus titres determined by plaque assay. Error bars represent standard deviation (SD) of results from three experiments assayed in
triplicate. (C) Northern blot analysis of purified mRNA extracted from CK cells infected with 16105 pfu wild type, parental virus, Beau-R (WT) and
replicates R1 and R2 of P4 BeauR-eGFPD5ab (left panel) or BeauR-hRlucD5ab and BeauR-IBVhRlucD5ab (right panel). Purified mRNA was not
quantified prior to loading on gel and is shown only to demonstrate that sg mRNAs were generated as expected. RNAs were hybridised with a DNA
probe specific to the IBV 39 UTR. Closed arrowheads indicate the sizes of sg mRNAs from Beau-R and open arrowheads indicating the altered sizes of
the sg mRNAs from the rIBVs. (D) Western blot analysis of reporter gene expression. Proteins in cell lysates of CK cells infected with wild type, parental
virus, Beau-R (WT) or P4 BeauR-eGFPD5ab (top panel) or BeauR-hRlucD5ab and BeauR-IBVhRlucD5ab (lower panel) were analysed by western blot
analysis using anti-IBV, anti-eGFP or anti-hRluc and anti-actin antibodies. Cell lysates from uninfected cells (M) were included as a negative control.
doi:10.1371/journal.pone.0067875.g003
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Figure 4. Analysis of reporter gene expression. (A) Expression of eGFP observed by fluorescence microscopy in CK cells infected with R1 and R2
of BeauR-eGFPD5ab and BeauR-eGFPDIR. (B) hRluc expression, as relative light units (RLU), was detected in CK cells infected with R1 of BeauR-
hRlucD5ab, BeauR-hRlucDIR, BeauR-hRlucD3ab and with R1 and R2 of BeauR-IBVhRlucD5ab. Error bars represent SD of results from three experiments
assayed in triplicate.
doi:10.1371/journal.pone.0067875.g004
Figure 5. Amino acid alignment of mutated hRluc gene in the R1 of BeauR-IBVhRlucD5ab. The amino acid sequence of the mutated hRluc
gene (hRluc*) identified in R1 of BeauR-IBVhRlucD5ab is shown aligned to the hRluc gene sequence. The modified region in hRluc* sequence is
underlined.
doi:10.1371/journal.pone.0067875.g005
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Figure 6. Characterisation of rIBVs with replacement of the IR with eGFP or hRluc. (A) Monolayers of CK cells were infected with wild type
virus (Beau-R), control virus (BeauRDIR) or P4 of rIBVs BeauR-eGFPDIR or BeauR-hRlucDIR and cytopathic effect analysed by plaque assay. (B) Growth
kinetics of Beau-R, BeauRDIR and R1 of BeauR-eGFPDIR and BeauR-hRlucDIR in CK cells. Extracellular virus was harvested at various times post
infection and the progeny virus titres determined by plaque assay. Error bars represent SD of results from three experiments assayed in triplicate. (C)
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produced from an introduced TRS may not be as efficient as that
for normal viral sg mRNA transcription. Introduction of a new
TRS within the IR did not result in synthesis of a new mRNA
species.
Western blot analysis identified that the hRluc protein was
expressed from BeauR-hRlucD3ab R1 in infected CK cells but not
from R2 (Figure 8D). This confirmed that the sequence mutations
observed within the hRluc gene of BeauR-hRlucD3ab R2 affected
the expression of hRluc protein, and also potentially prevented
transcription of a sg mRNA for the E protein. Luciferase activity
was detected in cell lysates from cells infected with R1 (Figure 4B)
and peak levels at 24 hpi were found to be similar to those
produced by rIBV BeauR-hRlucDIR. Characterisation of R1 and
R2 of BeauR-hRlucD3ab demonstrated that rescue of rIBVs may
result in differences arising between replicates of the same virus.
Stability of rIBVs expressing heterologous proteins
In order to further assess the potential for using rIBVs as
vaccine vectors it was necessary to analyse the stability of each
rIBV with respect to the ability to maintain expression of the
heterologous gene. The genetic stability of each rIBV was initially
assessed by blind passage of the rIBVs on CK cells and
Comparison of growth kinetics of Beau-R, BeauRDIR and R1 and R2 of BeauR-eGFPDIR in CK cells. Extracellular virus was harvested at various times
post infection and the progeny virus titres determined by plaque assay. Error bars represent SD of results from three experiments assayed in triplicate.
(D) Northern blot analysis of purified mRNA extracted from CK cells infected with 16105 pfu wild type, parental virus, Beau-R (WT) and replicates R1
and R2 of P4 BeauR-eGFPDIR (left panel) or BeauR-hRlucDIR (right panel). Purified mRNA was not quantified prior to loading on gel and is shown only
to demonstrate that sg mRNAs were generated as expected. RNAs were hybridised with a DNA probe specific to the IBV 39 UTR. Closed arrowheads
indicate the sizes of sg mRNAs from Beau-R and open arrowheads indicating the altered sizes for the sg mRNAs produced from the rIBVs. (E) Western
blot analysis of reporter gene expression. Proteins in cell lysates of CK cells infected with wild type, parental virus, Beau-R (WT) or P4 BeauR-eGFPDIR
(top panel) or BeauR-hRlucDIR (lower panel) were analysed by western blot analysis using anti-IBV, anti-eGFP or anti-hRluc and anti-actin antibodies.
Cell lysates from uninfected cells (M) were included as a negative control.
doi:10.1371/journal.pone.0067875.g006
Figure 7. Sequence analysis of sg mRNAs expressing the reporter genes EGFP and hRluc from rIBVs BeauR-eGFPDIR and BeauR-
hRlucDIR. Total RNA was extracted from CK cells infected with (A) BeauR-eGFPDIR or (B) BeauR-hRlucDIR and the reporter gene sg mRNAs amplified
by RT-PCR. The sg mRNAs corresponding to eGFP and hRluc were aligned with the reporter gene sequences in the rIBV genomes to identify the
origin of the leader-body junctions (in bold). Sequence analysis shows that the sg mRNAs originate from the natural IR TRS and not from the inserted
copy of the canonical IBV TRS (in bold, italics). Genomic sequence is shown below and sg mRNA sequence above. The M gene termination codon is
shown with a dashed underline and the eGFP (A) or hRluc (B) initiation codon is underlined.
doi:10.1371/journal.pone.0067875.g007
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characterisation by RT-PCR analysis to determine the presence,
or absence, of the heterologous gene (Table 2; Figure 9). As
summarized in Table 3, we observed instability arising at different
passage numbers, depending on the rIBV, as shown by the gradual
loss of the PCR product representing the heterologous gene, and
the appearance of smaller PCR products indicating deletion of the
heterologous gene sequences (Figure 9). Passaging of rIBVs in
embryonated hens’ eggs revealed the same pattern of genetic
instability for each virus highlighting that selection pressures were
the same in vitro and in ovo (data not shown). An investigation of
these smaller PCR products demonstrated that each one
represented a different deletion corresponding to the inserted
heterologous gene sequence, as shown by examples in Figure 10.
Sequence analysis of the smallest PCR product generated during
passage of BeauR-eGFPDIR demonstrated that deletions were not
limited to the heterologous gene, and could expand into flanking
regions of accessory genes (Figure 10A) as also demonstrated in a
study by Shen et al. [24].
Comparison of the stability of the rIBVs showed similar results
for each reporter gene, with the loss of eGFP detectable at P7
when replacing the IR and at P8/P9 when replacing Gene 5. The
loss of hRluc was detectable at P8 when replacing the IR and also
at P8/P9 when replacing Gene 5. Codon-optimisation of the
hRluc gene in BeauR-IBVhRlucD5ab resulted in an increase in
stability by 1–2 passages. Sequence analysis of BeauR-hRlucD3ab
identified that by P4 errors had arisen in the region of the hRluc
gene, which were responsible for the loss of hRluc expression from
R2. Despite this, RT-PCR analysis indicated that large-scale
deletions, as evidenced by smaller PCR products, did not arise
until P7. In comparison, smaller PCR products representing
possible deletions were observed as early as P5 for BeauR-
hRlucD3ab R1, which may have resulted from the 3 nt deletion
observed at P4 within the inserted TRS for expression of the E
gene. Overall, analysis of the stability of BeauR-hRlucD3ab
identified that passaging of this rIBV led to the rapid accumulation
of sequence errors and subsequently deletion of the heterologous
gene sequence.
In this study we also compared the genetic stability of rIBVs
following passaging at a low MOI of 0.01 to prevent the potential
accumulation of D-RNAs, a known consequence of passaging
Figure 8. Characterisation of rIBVs with replacement of ORFs 3a and 3b with hRluc. (A) Monolayers of CK cells were infected with wild type
virus (Beau-R), control virus (BeauRD3ab) or P4 of rIBV BeauR-hRlucD3ab and cytopathic effect analysed by plaque assay. (B) Growth kinetics of Beau-
R, BeauRD3ab and R1 of BeauR-hRlucD3ab in CK cells. Extracellular virus was harvested at various times post infection and the progeny virus titres
determined by plaque assay. Error bars represent SD of results from three experiments assayed in triplicate. (C) Northern blot analysis of purified
mRNA extracted from CK cells infected with 16105 pfu wild type, parental virus, Beau-R (WT) and replicates R1 and R2 of P4 BeauR-hRlucD3ab.
Purified mRNA was not quantified prior to loading on gel and is shown only to demonstrate that sg mRNAs were generated as expected. RNAs were
hybridised with a DNA probe specific to the IBV 39 UTR. Closed arrowheads indicate the sizes of sg mRNAs from Beau-R and open arrowheads
indicating the altered sizes for the sg mRNAs produced from the rIBVs. The new sg mRNA (labelled E), synthesised from the inserted TRS for
expression of the E protein, is indicated with an open arrowhead. (E) Western blot analysis of reporter gene expression. Proteins in cell lysates of CK
cells infected with wild type, parental virus, Beau-R (WT) or P4 BeauR-hRlucD3ab R1 and R2 were analysed by western blot with anti-IBV, anti-hRluc
and anti-actin antibodies. Cell lysates from uninfected cells (M) were included as a negative control.
doi:10.1371/journal.pone.0067875.g008
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IBVs in cell culture [43,49]. Analysis of the genetic stabilities of R1
from each of the rIBVs expressing hRluc, following passage at an
MOI 0.01, identified that genetic stability was maintained longer
for rIBVs in which Gene 5 was replaced (Figure 11). Expression of
hRluc, and IBVhRluc, was stable for at least 12 passages in cell
culture following replacement of Gene 5; an increase of at least 4
passages when compared to passage at a higher MOI. A difference
of only one passage number was observed for the replacement of
the IR while no increase in stability was observed for replacement
of ORF3a and 3b, suggesting the stability of these rIBVs could not
be improved. Overall these results indicated that the replacement
of Gene 5 resulted in rIBVs with the highest genetic stability and
Figure 9. Analysis of genetic stability of the rIBVs. Replicates R1 and R2 of BeauR-eGFPD5ab, BeauR-eGFPDIR, BeauR-hRlucD5ab, BeauR-
IBVhRlucD5ab, BeauR-hRlucDIR and BeauR-hRlucD3ab were blind passaged on CK cells from P4 to P12. Extracellular virus was harvested 24 hpi and
RNA analysed by RT-PCR in which the virus genomes were amplified using primers flanking the inserted reporter genes (Table 2) and visualised by gel
electrophoresis. Observation of expected PCR products representing genetically stable virus is indicated to the right by closed arrowheads. Genetic
instability was attributed to the appearance of smaller PCR products, identified by open arrowheads, representing deletions within the reporter gene
sequences. Size markers (L) in base pairs are indicated to the left.
doi:10.1371/journal.pone.0067875.g009
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that this stability could be improved by controlling the MOI at
which virus is passaged.
Discussion
In this study we have confirmed that heterologous gene
sequences can be inserted into the IBV Beaudette genome,
resulting in the expression of non-IBV proteins and therefore
supporting the potential development of IBV-based vaccine
vectors. Infectious rIBVs were obtained with the reporter gene
hRluc replacing the nonessential genes Gene 5, IR and ORFs 3a
and 3b of Gene 3, and with the reporter gene eGFP replacing
Gene 5 and the IR. An additional rIBV was obtained in which
Gene 5 was replaced with an IBV codon-optimised version of the
hRluc gene, IBVhRluc. The genetic stability of rIBVs expressing
heterologous genes was primarily found to be dependent on the
genomic location at which heterologous genes were incorporated
with the replacement of Gene 5 yielding the most stable
recombinants; stable expression of wild type, and codon-
optimised, hRluc was achieved for at least 12 passages in vitro
when passaged at an MOI of 0.01.
Coronaviruses have several attributes that favour them as an
attractive vehicle for development as vaccine vectors. Coronavi-
ruses possess large genomes and, in all cases, accessory genes have
been identified that are not essential for virus replication and can
therefore be deleted, thus providing suitable targets for the
insertion of heterologous genes [27,40,41,50–52]. The replace-
ment of accessory genes with heterologous genes has been
successfully demonstrated for a number of coronaviruses in recent
years, including IBV, and has often been shown to result in more
genetically stable recombinant viruses when compared to expres-
sion of heterologous genes from novel sg mRNAs [23–27]. For this
reason we chose to focus on rIBV constructs in which heterologous
genes were used to replace existing accessory genes and
demonstrated that, in the absence of deletions within the reporter
gene sequence, such as observed for BeauR-hRlucD3ab R2,
heterologous protein expression was possible from three different
regions of the IBV genome: Gene 5, the IR and ORFs 3a and 3b
(Figures 3D, 6E and 8D).
The location of a heterologous gene within a coronavirus
genome was shown to be one of the determining factors in the
genetic stability of recombinant coronaviruses [29] and was
Figure 10. Schematic representation of rIBV genetic instability.
Regions flanking the reporter gene sites of rIBVs following passage to
P8 on CK cells were amplified by RT-PCR, non-wild type PCR products
were cloned and sequenced. Sequence analysis of independently
selected clones identified that the RT-PCR products contained a variety
of deleted sequences when compared to the sequences of the reporter
gene containing IBV cDNAs used for generating the rIBVs. Schematics
representing deletions are shown for wild type (A) BeauR-eGFPDIR and
(B) BeauR-hRlucD5ab with three example deletions of each highlighting
loss of eGFP or hRluc gene sequences. Relevant TRS sequences are
shown expanded above each genome.
doi:10.1371/journal.pone.0067875.g010
Table 2. Genetic Stability PCR Primers and Expected Product Sizes.
Virus Primer Sequencesa Genome Locationb PCR Product (bp)
BeauR-eGFPD5ab F: GAGCTATTAACGGTGTTACC 25306–25325 963
BeauR-hRlucD5ab R: AATCTAATCCTTCTCTCAGA 25741–25760 1179
BeauR-IBVhRlucD5ab 1179
BeauR-eGFPDIR F: GAATGGTGTTCTTTATTG 24945–24962 1087
BeauR-hRlucDIR R: TCTAACACTCTAAGTTGAG 25549–25567 1303
BeauR-hRlucD3ab F: TGACGAATTGTCAAAATG 23457–23474 1916
R: AGACAGACACGCAAACACTG 24761–24780
aF = forward and R = reverse primer.
bAs derived from the sequence of the wild type Beau-R strain.
doi:10.1371/journal.pone.0067875.t002
Table 3. Genetic Stability of rIBVs.









aFinal passage number achieved including rescue passages, P0–P4
doi:10.1371/journal.pone.0067875.t003
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subsequently confirmed in this study. We have demonstrated that
the genetic stability of the rIBVs correlated with the location of a
reporter gene, which indirectly correlated with the level of
sequence modifications required in order to accommodate the
reporter gene in the IBV genome. The replacement of Gene 5
with hRluc or IBVhRluc yielded rIBVs that were stable to at least
P12 when passaged at an MOI of 0.01 on CK cells (Figure 11).
When Gene 5 was replaced with eGFP rIBVs were stable to P8/
P9 in initial experiments; a similar level of stability was observed
by Youn et al. [27] in which a rIBV expressing eGFP from
replacement of ORF 5a alone was stable to P5 in Vero cells. In our
initial experiments no difference in stability was observed between
rIBVs expressing heterologous genes from Gene 5 or from the IR
with all viruses stable to between P7 and P9 (Figure 9). However,
in contrast to the replacement of Gene 5 where stability was
increased by at least 4 passages, no difference was observed in the
stability of BeauR-hRlucDIR when passaged at an MOI of 0.01.
This suggests that controlling the MOI at which viruses are
passaged may only be beneficial for some rIBV constructs; in this
case the replacement of Gene 5.
In contrast to Shen et al., who obtained a rIBV, genetically
stable up to P15, by replacing ORFs 3a and 3b with firefly
luciferase [24], we observed that insertion of heterologous
sequences in this position resulted in viruses arising rapidly with
deletions within the hRluc gene; appearing from P5 onwards
(Figures 9 and 11). This variation in observed stability may be
accounted for by the intrinsic differences between the luciferase
genes. However, a previous study identified that in the case of
MHV the firefly luciferase was less stable than hRluc when
inserted at the same genome position [28]. In both this study and
that of Shen et al. expression of heterologous genes following
replacement of IBV ORFs 3a and 3b required further modifica-
tion to the virus sequences to ensure the continued transcription of
ORF 3c, the E protein. The contradictory observations regarding
the expression of heterologous genes from IBV Gene 3 suggest the
possibility that not only the position of the heterologous gene is
important for stability, but also the way in which genome
sequences are modified to accommodate the heterologous gene.
Interestingly, for BeauR-hRlucD3ab, despite deletions arising
rapidly in the population from P5 onwards, we observed the
expression of hRluc up to P11 in initial experiments and up to at
least P12 when passaged at an MOI of 0.01 (data not shown). This
was in contrast to the replacement of Gene 5 or the IR, where
once deletions were detected loss of the heterologous gene from
the virus population was complete following 1–3 further passages.
Although the replacement of ORFs 3a and 3b led to rapid
accumulation of deletion variants within the virus population it
took longer for these variants to become the dominant population
compared to the replacement of Gene 5 or the IR. These
observations highlight the requirement to analyse stability by
sequence analysis rather than expression of the heterologous
protein alone. Overall, our results raise the suggestion that the
replacement of ORFs 3a and 3b may be a suitable target if the
sequence of the construct can be designed to prevent errors arising
around the inserted TRS for expression of the E protein that
Figure 11. Analysis of the genetic stability of the rIBVs following passage at a low MOI. Replicates R1 of BeauR-hRlucD5ab, BeauR-
IBVhRlucD5ab, BeauR-hRlucDIR and BeauR-hRlucD3ab were passaged on CK cells from P4 to P12 at an MOI of 0.01. Extracellular virus was harvested
24 hpi and RNA analysed by RT-PCR in which the virus genomes were amplified using primers flanking the inserted reporter genes (Table 2) and
visualised by gel electrophoresis. Observation of expected PCR products representing genetically stable virus is indicated to the right by closed
arrowheads. Genetic instability was observed for BeauR-hRlucDIR and BeauR-hRlucD3ab as indicated by the appearance of smaller PCR products
(open arrowheads) and represented deletions within reporter gene sequences. Size markers (L) in base pairs are indicated to the left.
doi:10.1371/journal.pone.0067875.g011
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undoubtedly led to the rapid expansion of deletions within this
region.
In order to accommodate the expression of heterologous genes
via novel sg mRNAs artificially inserted TRSs are also required
upstream of the heterologous gene. In this study two such TRSs
were required: (1) for expression of E from BeauR-hRlucD3ab and
(2) for expression of the reporter genes from BeauR-eGFPDIR and
BeauR-hRlucDIR. As discussed above mutations were encoun-
tered within the TRS for E from BeauR-hRlucD3ab that likely
contributed to the overall instability of the virus in this region. The
design of the TRS may have played a role in this through
inefficient synthesis of the E sg mRNA, and suggests a sub-optimal
TRS design. Similarly, in the DIR rIBVs the TRS inserted for
expression of eGFP and hRluc may be sub-optimal thus leading to
the use of the existing non-canonical TRS-B for the IR. In both
cases there was limited complementarity between the artificially
inserted consensus TRS and the leader sequence of the virus
beyond the CUUAACAA sequence. It is possible that increasing
this complementarity would lead to more stable gene expression
or, in the case of the IR, the switch in transcription occurring at
the artificial TRS and not the natural non-canonical IR TRS.
However, as discussed in the design of the artificial TRS’s the full
extent of the TRS required for IBV sg mRNA transcription has
yet to be elucidated and increased knowledge in this area would be
required to better design recombinant viruses expressing heterol-
ogous genes as additional transcripts.
Our results confirmed those from other studies that the cause of
virus instability, with respect to expression of the heterologous
gene, resulted from deletion of the heterologous gene sequences
[24,25,27,28]. The proposed mechanism for this is via homolo-
gous, or non-homologous, recombination events between sequenc-
es of virus genomes, such as TRSs that would result in the loss of
the heterologous gene and it is probably also the situation with the
rIBVs analysed in this study. Following analysis of the types of
deletions arising in the virus populations we observed that the
majority of deletions began within, or close to, the TRS associated
with transcription of the heterologous gene (Figure 10). As these
are regions of high similarity it suggests that they are potential
hotspots for homologous recombination events during coronavirus
replication. In rIBVs in which the heterologous genes replaced the
IR and ORFs 3a and 3b sequences, an additional TRS was
inserted into the IBV genome, when compared to wild type
sequence or Gene 5 replacement. The presence of an additional
TRS would have provided an additional target for recombination
events and may in part explain the difference in stability observed
for each rIBV construct.
In this study we also sought to examine the effects of codon-
optimisation of heterologous genes to establish whether there
would be any advantages in designing vaccine vectors with this in
mind. Codon-optimisation of genes has been shown to increase the
translational efficiency of heterologous genes in different cell types
by balancing the tRNA requirements of the gene with those most
available in a particular host cell type. Expression of viral genes
has also been shown to be increased by codon-optimisation
[53,54] or decreased by codon-deoptimisation [55], and this may
be important for expression of heterologous genes from vaccine
vectors. Codon usage may also have a bearing on RNA stability by
altering the secondary structures of RNAs, and so changes to
codon usage may affect the overall stability of viruses expressing
heterologous genes. We took the approach of altering every codon
of the heterologous genes to those preferentially used by IBV in
order to find out if reporter protein expression and/or virus
stability would be improved. We found that protein expression of
codon optimised hRluc, IBVhRluc R2, was approximately 2-log10
lower than standard hRluc from 24 hpi when expressed in CK
cells (Figure 4B) demonstrating that in this case translation
efficiency was reduced by codon-optimisation. It is possible that
codon optimisation has resulted in the introduction of sequence
elements that limits the efficiency of protein expression in avian
cells, thus counteracting the original optimisation of Rluc by
Zhuang et al. for expression in mammalian cells [56]. Our results
suggest that codon-optimisation may potentially result in improved
virus stability, as a 1 or 2 passage increase in stability was observed
for BeauR-IBVhRlucD5ab during initial passaging experiments
compared to BeauR-hRlucD5ab. However, a complete investiga-
tion of the translation efficiency of a codon optimised gene, using
synthetic RNAs, would be required if such a modification were to
be pursued for vaccine development.
Overall our data has shown that a number of rIBVs were
capable of expressing a heterologous gene, offering the potential
for developing IBV as a vaccine vector. The stability of these
rIBVs varied depending on genome location of the heterologous
gene and/or the level of modification to the IBV genome required
for expression of the gene, or to ensure expression of essential IBV
proteins following insertion of the heterologous gene. The
replacement of Gene 5 proved to be the most successful in terms
of stability while the replacement of ORFs 3a and 3b was found to
be the least stable. Overall, using the reporter genes described in
this work, the type of heterologous gene inserted was generally
found to have little effect on protein expression or stability.
However, as not all eGFP-based rIBVs were rescued comparison
to the corresponding hRluc-based rIBVs is limited. Whilst we
demonstrated that heterologous proteins could be expressed from
several genomic locations a more in-depth analysis quantifying sg
mRNA, and protein, expression would be required to determine
the optimal design of potential rIBV vectors expressing additional
viral proteins.
The data presented demonstrates that IBV could be used as a
vaccine vector to generate bivalent vaccines capable of protecting
chickens against IB as well as a second disease based on expression
of heterologous genes replacing Gene 5. The coronavirus spike
gene is a known determinant of viral tropism [57] and we have
previously demonstrated the ability of swapping spike genes
between strains of IBV [46,57]. This raises the possibility of
exchanging the spike gene of rIBVs expressing heterologous genes
with that of a different coronavirus in order to alter the cellular
tropism of the virus and investigate the potential for utilising IBV
as a broader vector for use in non-avian animal species and
humans.
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